Low selenium status increases the risk of hepatic cancer

Study with participation of the Charité in Berlin – Prof. Dr. Lutz Schomburg*

*https://expendo.charite.de/forschung/ag_lutz_schomburg/
In a press statement issued in July (N° 245), the WHO presented the latest findings with regard to selenium status and cancer risk. A large-scale prospective European trial investigated the impact of the selenium status on the hepatic cancer risk.\(^1\)

The trial delivers two important findings:

1. The selenium status of Europeans is suboptimal.
2. A lower selenium level (≤ 80.5 μg/l selenium in the serum) is associated with a significantly higherrisk of hepatic cancer.

Apart from hepatitis, alcohol or aflatoxins, a suboptimal selenium status would be an additional risk factor for hepatic cancer.

### Hepatic cancer

In 2012, there were approx. 782,000 new cases of hepatic cancer worldwide. Almost 746,000 of those afflicted with hepatic cancer died from the disease in 2012. This represents 9.1% of all deaths caused by cancer in 2012. Hepatic cancer is thereby the second most frequent cause of death from cancer. In the EU, 52,000 new hepatic cancer cases occurred in 2012 and 49,000 of all afflicted with the disease died. The prognosis of hepatic cancer is very poor with a total relationship of mortality to incidence of 0.95.\(^2\)

### EPIC

EPIC (European Prospective Investigation into Cancer and Nutrition) is a large-scale prospective cohort trial with more than 520,000 participants from ten European countries. For the embedded case control study, the selenium status of 261 cancer cases was prospectively compared with 261 controls.\(^1\) In addition, the serum selenium and the selenoprotein P concentration was investigated.

The case group included 121 patients with hepatocellular carcinoma (HCC), 100 patients with gallbladder and hepatic duct cancer (GBTC) as well as 40 with intrahepatic bile duct cancer (IHBC).

### Significantly lower selenium status with hepatic cancer

Patients with HCC and GBTC showed significantly lower serum selenium values (HCC: 71.3 vs. 85.2 μg/l; p<0.001; GBTC 82.1 vs. 85.9; p=0.041).\(^1\) For selenoprotein P, the transport protein for selenium, a significant difference to the control group could only be demonstrated for HCC (4.3 vs. 5.4 mg/l; p<0.001). In total, there was a strong significant correlation between the serum concentration of selenium and selenoprotein P (r=0.62; p≤0.001).

### Suboptimal selenium status increases hepatic cancer risk almost tenfold

The comparison between a serum selenium concentration of ≤80.5 μg/l and ≥94.5 μg/l showed a significant reduction of the relative risk for HCC by 82% (OR 0.18; 95% CI 0.05–0.66; p=0.016). This means that an increase of the serum selenium value by 20 μg/l reduces the HCC risk by 59% (OR 0.41; 95% CI 0.23–0.72). Even more significant is the relationship for selenium transport protein selenoprotein P. A suboptimal selenoprotein P concentration increased the hepatic cancer risk tenfold (≤4.9 mg/l vs. ≥6.4 mg/l: OR 0.09; 95% CI 0.03–0.32; p<0.0001).
Suboptimal selenium status – selenium deficiency

The classification of the selenium status into tertiles (≤ 80.5 μg/l vs. 80.6–94.4 μg/l; ≥ 94.5 μg/l serum selenium concentration) significantly shows that no massive selenium deficiency must be present for an increased cancer risk. At the same time, a significantly improved protection is only achieved at a serum selenium concentration of ≥ 94.5 μg/l (Table 1).

The reference range for selenium in Germany lies between 80–120 μg/l selenium in the serum. A selenium deficiency in the serum begins at values below 80 μg/l. The selenium status for Germans on the average lies even lower (men 74.3 μg/l, women 73.2 μg/l selenium in the serum). However a reduction of hepatic cancer risk can be expected only at serum selenium concentrations in the upper reference range.

### Association between selenium status and hepatic cancer risk

<table>
<thead>
<tr>
<th>Serum selenium concentration</th>
<th>HCC OR (95% CI)</th>
<th>Selenoprotein P-concentration</th>
<th>HCC OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 80.5 μg/l</td>
<td>Reference</td>
<td>≤ 4.9 mg/l</td>
<td>Reference</td>
</tr>
<tr>
<td>80.6–94.4 μg/l</td>
<td>0.88 (0.35–2.21)</td>
<td>5–6.3 mg/l</td>
<td>0.43 (0.18–0.99)</td>
</tr>
<tr>
<td>≥ 94.5 μg/l</td>
<td>0.18 (0.05–0.66)</td>
<td>≥ 6.4 mg/l</td>
<td>0.09 (0.03–0.32)</td>
</tr>
<tr>
<td>p-trend</td>
<td>0.016</td>
<td>p-trend</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>per 20 μg/l</td>
<td>0.41 (0.23–0.72)</td>
<td>per 1.5 mg/l</td>
<td>0.37 (0.21–0.63)</td>
</tr>
</tbody>
</table>


Table 1

### Bibliography

Brochures

We gladly offer you extensive information on the topic “Selenium and oncology” – for expert groups and patients.

Order by e-mail at: information@biosyn.de (key word “Onco folder”)

Newsletter

Subscribe to our online newsletter “biosynNews international” and “biosynNews Export” to obtain current information.

Order by e-mail at: information@biosyn.de (key words “biosynNews international” and “biosynNews Export”)

Further information

If you have specific questions on this topic, please call us at: +49 (0) 711 575 32-00

We would be glad to provide you with greater quantities of reference literature for your patients without charge.

biosyn Arzneimittel GmbH
Schorndorfer Straße 32
70734 Fellbach, Germany
information@biosyn.de

www.biosynpharma.com
www.biosyn.de

Managing Director: Dr. Thomas Stiefel and Ortwin Kottwitz
Commercial Register: County Court Stuttgart HRB 262712
Place of performance: Fellbach, Legal venue Stuttgart

© biosyn 2018
Picture credits: Cover photo © bloodstone/iStockphoto